Share
16,294 Posts.
lightbulb Created with Sketch. 6193
clock Created with Sketch. 23/05/17
08:14
Share
Originally posted by 8thmaker
↑
Yankee - the point is you claimed Vericel had completed "just a Phase 2 trial" (singular) that failed, and implied that MSB should therefore have no problem getting RAT designation for multiple products (incidentally, it's actually called RMAT designation now). The reality is that Vericel has completed three trials with this product, all of which met their primary endpoints. I'm not sure what you think you achieve by misrepresenting this - but in any case, I just wanted to point out the facts in case others are unfamiliar with Vericell. I'm not saying MSB can't get RMAT designation(s), I'm just saying that's not necessarily a slam dunk, as they don't have the same amount of clinical evidence in favour of any of their products at this point in time.how the treatment works, but the improvement in clinical outcomes is clear. Clinical outcomes are what matter most - to patients, regulators and payors.
Expand
(20min delay)